SAB Biotherapeutics Inc.

11/29/2023 | Press release | Distributed by Public on 11/29/2023 06:33

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes